Can mouth health and chewing help explain arterial stiffness in healthy adults

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

INN.oral.HEALTH is a cross-sectional sub-study within the INN.HEALTH prevention cohort in Innsbruck. It adds standardized assessments of oral structure and function to see if they improve understanding of central arterial stiffness, measured by carotid‑femoral pulse wave velocity. The study compares a base cardiovascular model with an extended model that includes the oral test battery. It examines whether oral health, chewing, and tongue strength contribute additional explanatory value for vascular aging beyond known risk factors.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* adults meeting the INN.HEALTH cohort eligibility criteria, including age ≥18 years, residence in Innsbruck City or Innsbruck-Land, and capacity to consent
* additionally at Visit 4, participants must report being able to safely chew and, where required, swallow the standardized test materials

Exclusion Criteria:

* temporalmandibular joint disorders
* severe jaw joint complaints
* active dental treatment at the time of assessment
* inability to safely chew/swallow the standardized test materials.

Where it's running

• VASCage Study Site
  Innsbruck, Tyrol, Austria Recruiting

Study contacts

• Principal investigator: Petr Simurda, MD — VASCage GmbH
• Study coordinator: Simon Sollereder, MSc
• Email: simon.sollereder@vascage.at
• Phone: +43 664 1004838

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Kidney and Heart Health in Adults with Type 2 Diabetes and CKD Treated with Semaglutide in China

  This study tests whether semaglutide injections help kidney and heart health in adults with type 2 diabetes and chronic kidney disease.

  Recruiting Phase 4 Novo Nordisk A/S · Fuyang, Anhui and 25 other locations · NCT07900438

• Understanding why some people see bigger LDL drops after starting ezetimibe

  This study tests what factors predict how much a person’s LDL cholesterol drops after starting ezetimibe, to help tailor cholesterol treatment.

  Recruiting Phase 4 Universidade do Porto · Porto · NCT07839741

• Zenagamtide vs insulin glargine in type 2 diabetes with heart risk

  This trial tests whether weekly injections of zenagamtide can lower blood sugar and body weight better or differently than insulin glargine in people with type 2 diabetes and high cardiovascular risk who are on 1–3 other diabetes medicines.

  Recruiting at 56 sites Phase 3 Novo Nordisk A/S · Birmingham, Alabama and 329 other locations · NCT07797335

• Sleep and arterial function in hypertensive patients with poor sleep quality

  This trial tests whether using cognitive-behavioural therapy for insomnia can improve artery health and well-being in adults with high blood pressure and poor sleep.

  Recruiting Unidade Local de Saúde do Alto Ave, EPE · Guimarães, Braga District · NCT07789535

• Large language models for turning structured dental radiology data into narrative reports

  This study tests whether a language model can convert organized dental X‑ray findings into clear, complete radiology reports.

  Recruiting Hospital of the Ministry of Interior, Kielce, Poland · Kielce, Świętokrzyskie Voivodeship · NCT07676318

• SNRK and vascular aging in adults

  This study tests whether SNRK related signals in vascular cells relate to aging of the arteries in adults.

  Recruiting Tianjin Medical University · Tianjin, Tianjin Municipality · NCT07591337

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.